SEOUL, Jan. 12 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Thursday it will invest 7.5 trillion won (US$6 billion) to build a new biomedicine production complex west of Seoul. Samsung Biologics CEO John Rim said in the J.P. Morgan Healthcare Conference in San Francisco that the new [...]
SEOUL, Oct. 11 (Korea Bizwire) — Samsung Group’s de facto leader Lee Jae-yong on Tuesday attended the opening ceremony of the fourth plant of Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, in a sign of the group’s dedication to nurture biopharmaceuticals as one of its next growth drivers. The plant, which [...]
SEOUL, Aug. 12 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday it has tentatively agreed to work with multinational pharmaceutical company AstraZeneca on biopharmaceutical contract manufacturing. The company said in a regulatory filing that it signed a letter of intent on the cooperation in a deal valued [...]
SEOUL, July 18 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, on Monday signed a land purchase contract worth 426 billion won (US$323 million) to build a second campus inside a free economic zone west of Seoul. The deal signed between Incheon metropolitan city and Samsung Biologics would allow [...]
SEOUL, June 2 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, has established a one-stop production capability for manufacturing messenger RNA (mRNA) vaccines by newly adding a mRNA vaccine substance production facility at its plant, a company official said Thursday. According to the official, Samsung has completed the addition [...]
SEOUL, May 24 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, is shutting down its joint venture with multinational pharmaceutical company AstraZeneca Plc., a company official said Tuesday, due to the suspension of the development of a biosimilar product. The move came two months after Samsung Biologics’ board approved [...]
SEOUL, April 20 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Wednesday it has completed the first payment to acquire the U.S. drugmaker’s entire stake in Samsung Bioepis. Earlier, Samsung Biologics reached a deal with Biogen to purchase the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 [...]
SEOUL, March 29 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, aims to expand its presence in the global market through full ownership of Samsung Bioepis, its chief executive said Tuesday. Samsung Biologics is the leading contract development and manufacturing organization (CDMO) specializing in the development and manufacturing of [...]
SEOUL, Jan. 28 (Korea Bizwire) — Samsung Biologics Co., the biotech arm of South Korea’s Samsung Group, said Friday that it has reached a deal with Biogen Inc. to buy the U.S. drugmaker’s entire stake in Samsung Bioepis for US$2.3 billion. Currently, Biogen owns 50 percent minus one share in Samsung Bioepis, the joint venture [...]
SEOUL, Jan. 13 (Korea Bizwire) — Samsung Biologics, a major South Korean contract drug manufacturer, said Thursday it plans to start building a fifth plant this year to meet rising orders. The company’s fourth plant, currently under construction, is set to be partially operational from October starting with a bioreactor capacity of 60,000 liters, CEO [...]